NASDAQ / LIVE COMPANY INTELLIGENCE

ProQR Therapeutics N.V.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERPRQR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / PRQR COVERAGE

What’s moving ProQR Therapeutics N.V. now

Current reporting with the operating signal separated from the noise.

01
MarketBeat

ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 92.5% in July

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Stock Titan

[SCHEDULE 13D/A] ProQR Therapeutics N.V. Amended Major Shareholder Report

Investors are testing whether ProQR Therapeutics N.V.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Proqr Therapeutics N.v. (PRQR)

Proqr Therapeutics N.v. (PRQR)

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
ProQR Therapeutics N.V. (PRQR) Presents at Evercore 8th Annual Healthcare Conference Transcript

ProQR Therapeutics N.V. (PRQR) Presents at Evercore 8th Annual Healthcare Conference Transcript

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation

Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation

The development tests whether ProQR Therapeutics N.V. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
07
Chardan Capital Upgrades ProQR Therapeutics N.V (PRQR)

Chardan Capital Upgrades ProQR Therapeutics N.V (PRQR)

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
08
ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

The story matters when it changes ProQR Therapeutics N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest PRQR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-06-26 · Period 2026-06-26SEC ↗6-KOfficial SEC filingFiled 2026-06-25 · Period 2026-06-25SEC ↗4Official SEC filingFiled 2026-08-03 · Period 2026-07-31SEC ↗SCHEDULE 13D/AOfficial SEC filingFiled 2026-07-29SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-29SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-24SEC ↗4Official SEC filingFiled 2026-07-21 · Period 2026-07-17SEC ↗EFFECTOfficial SEC filingFiled 2026-07-15SEC ↗
EARNINGS / QUARTERLY TRACKER

ProQR Therapeutics N.V., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.